In early January 2026, Johnson & Johnson reported that nipocalimab (Imaavy) met primary and key secondary endpoints in the ...
Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...
Clinical Trials Arena on MSN
J&J’s Imaavy posts win in Phase II SLE trial
Imaavy will now progress to Phase III in SLE, though it will face strong competition from SLE market leader, Benlysta, if ...
Johnson & Johnson (JNJ) announced on Tuesday that nipocalimab, its experimental therapy for an autoimmune condition called ...
The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...
Which of the statements about the 2025 American College of Rheumatology guideline for the treatment of systemic lupus ...
Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...
Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...
Low baseline 25 (OH)D levels are associated with higher mortality and cardiovascular event risks among patients with systemic lupus erythematosus (SLE), with evidence of a U-shaped relationship ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback